Liu Jingbing, Lu Guanzheng, Liang Can, Tian Yifan, Jiang Ziyu
Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, PR China.
School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China.
Pathol Res Pract. 2023 Jan;241:154256. doi: 10.1016/j.prp.2022.154256. Epub 2022 Nov 28.
Colorectal cancer (CRC) is a deadly malignancy and therapeutic approaches for CRC are evolving every day. Anoikis is a key mechanism for programmed cell death of cancer cells that undergo anchorage-independent growth at a different matrix than the one which is expected. Yet, anoikis is a less studied mechanism of cell death in comparison to other mechanisms such as apoptosis. Relating to this, resistance to anoikis among cancer cells remains critical for improved metastasis and survival in a new environment evading anoikis. Since CRC cells have the ability to metastasize from proximal sites to secondary organs such as liver and promote cancer in those distant sites, a clear knowledge of the mechanisms essential for anchorage-independent growth and subsequent metastasis is necessary to counteract CRC progression and spread. Therefore, the identification of novel drug candidates and studying the roles of anoikis in assisting CRC therapy using such drugs can prevent anchorage-independent cancer cell growth. Additionally, the identification of novel biomarkers or therapeutic targets seems essential for implementing superior therapy, impeding relapse among malignant cells and improving the survival rate of clinical patients. As there are no reviews published on this topic till date, anoikis as a mechanism of cell death and its therapeutic roles in CRC are discussed in this review. In addition, several molecules were identified as therapeutic targets for CRC.
结直肠癌(CRC)是一种致命的恶性肿瘤,针对CRC的治疗方法日新月异。失巢凋亡是癌细胞程序性细胞死亡的关键机制,这些癌细胞在与预期不同的基质上进行非锚定依赖性生长。然而,与凋亡等其他机制相比,失巢凋亡是一种研究较少的细胞死亡机制。与此相关的是,癌细胞对失巢凋亡的抗性对于在逃避失巢凋亡的新环境中改善转移和生存仍然至关重要。由于CRC细胞有能力从近端部位转移到肝脏等次级器官,并在这些远处部位引发癌症,因此清楚了解非锚定依赖性生长及后续转移所必需的机制对于对抗CRC的进展和扩散至关重要。因此,鉴定新型候选药物并研究失巢凋亡在使用此类药物辅助CRC治疗中的作用可以防止非锚定依赖性癌细胞生长。此外,鉴定新型生物标志物或治疗靶点对于实施更优治疗、阻止恶性细胞复发以及提高临床患者生存率似乎至关重要。由于迄今为止尚未有关于该主题的综述发表,本综述讨论了失巢凋亡作为一种细胞死亡机制及其在CRC中的治疗作用。此外,还鉴定了几种分子作为CRC的治疗靶点。